|
M.A. Dzhelyalova, V.F. Semiglazov
Ways to improve endocrine therapy in postmenopausal women with ER+/HER2- breast cancer
|
№11 / 2021
|
|
K.S. Grechukhina (1, 2), K.A. Vorontsova (1), T.M. Kuko (1), A.A. Prosvirnov (1), I.P. Ganshina (3), E.V. Lubennikova (3), I.V. Kolyadina (4, 5), L.G. Zhukova (1)
Abemacyclib is a unique representative of the class of CDK4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer
|
№7 / 2021
|
|
M.A. Dzhelyalova, V.F. Semiglazov
Endocrine resistance in breast cancer treatment
|
№11 / 2020
|
|
D.D. Sakaeva, A.I. Iskhakova, R.I. Kunafina
CYCLIN-DEPENDENT KINASE INHIBITORS - NEW THERAPEUTIC OPTION FOR PATIENTS WITH HORMONE-DEPENDENT HER2-NEGATIVE BREAST CANCER: CLINICAL EXPERIENCE
|
№7 / 2018
|
|
L.G. Zhukova, E.I. Chichikov, O.O. Gordeeva, D.A. Filonenko
PALBOCICLIB – NEW POSSIBILITIES OF THERAPY OF HORMON-POSITIVE HER2-NEGATIVE BREAST CANCER
|
№17 / 2017
|
|
L.G. Zhukova, A.G. Manikhas
FIRST-LINE ENDOCRINE THERAPY OF HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE METASTATIC BREAST CANCER. TIME OF CHANGE AFTER A LONG-TERM CALM PERIOD
|
№17 / 2016
|
|
E.I. Borisova, G.V. Vyshinskaya, S.L. Gutorov, M.V. Stepanchenko
CLINICAL FEATURES OF INVASIVE LOBULAR BREAST CANCER
|
№17 / 2014
|
|
A.N. Lud, I.P. Ganshina
Bevacizumab (avastin) In The Treatment Of Patients With Breast Cancer
|
№18 / 2009
|
|
G.A. Dashian, V.F. Semiglazov, V.V. Semiglazov, N.Sh. Migmanova, O.A. T.T. Tabagua, A.G. Vasilyev
Breast Cancer And Pregnancy
|
№18 / 2009
|
Русский
